A Phase II Study to Evaluate the Effects of up to 12 Weeks of Pazopanib Dosing on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2017
Price : $35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Hereditary haemorrhagic telangiectasia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 31 Aug 2018 Biomarkers information updated
- 19 Apr 2017 Status changed from recruiting to discontinued.
- 08 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.